4MILLER WH, SCHIPPER HM, LEE JS, et al. Mechanisms of action of arsenic trioxide [J]. Cancer Res, 2002, 62 (14) : 3893- 3903.
5WAXMAN S, ANDERSON KC. History of the development of arsenic derivatives in cancer therapy [J]. Oncologist, 2001, 6 (suppl 2) :3-10.
6O'BRIEN DI, NALLY K, KELLY RG, et al. Targeting the Fas/Fas ligand pathway in cancer [J]. Expert Opin Ther Targets, 2005, 9(5) :1031-1044.
7BEBENEK M, DUS D, KOZLAK J. Fas and Fas ligand as prognostic factors in human breast carcinoma [J]. Med Sci Monit, 2006, 12(11) :CR457-461.
8ROJEWSKI MT, KORPER S, THIEL E, et al. Arsenic trioxideinduced apoptosis is independent of CD95 in lymphatic cell lines[J]. Oncol Rep, 2004, 11(2):509-513.
9ZHU J, OKUMURA H, OHTAKE S, et al. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/ CD95L system [J]. Oncol Rep, 2003, 10(3),705-709.
10KITAMURA K, MINAMI Y, YAMAMOTO K, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis [J]. Leukemia, 2000, 14(10) : 1748-1750.
